# Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.

> **NCT04262024** · PHASE1 · COMPLETED · sponsor: **Woman's Health University Hospital, Egypt** · enrollment: 120 (actual)

## Conditions studied

- Health Education

## Interventions

- **DRUG:** cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
- **DRUG:** cabergoline 1.5-2 mg/week).orally daily for 1 month without health education

## Key facts

- **NCT ID:** NCT04262024
- **Lead sponsor:** Woman's Health University Hospital, Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-05-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262024, "Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04262024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*